Market closedNon-fractional
Denali Therapeutics/DNLI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Denali Therapeutics
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
Ticker
DNLI
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
South San Francisco, United States
Employees
375
Website
www.denalitherapeutics.com
DNLI Metrics
BasicAdvanced
$3.4B
Market cap
-
P/E ratio
-$0.98
EPS
1.36
Beta
-
Dividend rate
Price and volume
Market cap
$3.4B
Beta
1.36
Financial strength
Current ratio
11.789
Quick ratio
11.345
Long term debt to equity
2.957
Total debt to equity
3.473
Management effectiveness
Return on assets (TTM)
-8.70%
Return on equity (TTM)
-11.33%
Valuation
Price to revenue (TTM)
11.466
Price to book
2.35
Price to tangible book (TTM)
2.35
Price to free cash flow (TTM)
-7.967
Growth
Revenue change (TTM)
191.13%
Earnings per share change (TTM)
-66.02%
3-year revenue growth (CAGR)
-4.58%
3-year earnings per share growth (CAGR)
25.71%
What the Analysts think about DNLI
Analyst Ratings
Majority rating from 16 analysts.
DNLI Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$102M
-14.74%
Profit margin
0.00%
NaN%
DNLI Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$1.30
-$0.72
-$0.86
-$0.68
-
Expected
-$0.68
-$0.80
-$0.80
-$0.70
-$0.68
Surprise
-290.08%
-10.28%
6.94%
-3.25%
-
DNLI News
AllArticlesVideos
Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies
GlobeNewsWire·2 months ago
Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data
Seeking Alpha·2 months ago
Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Denali Therapeutics stock?
Denali Therapeutics (DNLI) has a market cap of $3.4B as of July 27, 2024.
What is the P/E ratio for Denali Therapeutics stock?
The price to earnings (P/E) ratio for Denali Therapeutics (DNLI) stock is 0 as of July 27, 2024.
Does Denali Therapeutics stock pay dividends?
No, Denali Therapeutics (DNLI) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Denali Therapeutics dividend payment date?
Denali Therapeutics (DNLI) stock does not pay dividends to its shareholders.
What is the beta indicator for Denali Therapeutics?
Denali Therapeutics (DNLI) has a beta rating of 1.36. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Denali Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.